The distinctive nature of HER2-positive breast cancers.

@article{Burstein2005TheDN,
  title={The distinctive nature of HER2-positive breast cancers.},
  author={H. Burstein},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 16},
  pages={
          1652-4
        }
}
  • H. Burstein
  • Published 2005
  • Medicine
  • The New England journal of medicine
    • The history of HER2 and trastuzumab treatment is a triumphal narrative of translational research. Dr. Harold Burstein writes that like all good stories, this one has a profound lesson: not all breast cancers are the same. 
    View PDF
    373 Citations
    Highly Influencial Citations
    14
    Background Citations
    143
    Methods Citations
    8
    Results Citations
    2

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

        Paper Mentions

        Interventional Clinical Trial
        HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Anti-HER2 sdAb
        To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2 single domain antibody (sdAb) (Product Code Name: 99mTc-NM02 and 188Re-NM02) SPECT/CT imaging of HER2… Expand
        ConditionsBreast Cancer
        InterventionDrug
        Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
        July 2019 - September 2022
        Interventional Clinical Trial
        Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
        RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die… Expand
        ConditionsBreast Cancer
        InterventionBiological, Drug
        NSABP Foundation Inc
        February 2000 - March 2020
        Interventional Clinical Trial
        Overcoming Endocrine Resistance in Metastatic Breast Cancer
        Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front… Expand
        ConditionsMetastatic Breast Cancer
        InterventionDrug
        Consorzio Oncotech
        November 2007 - January 2017
        News Article
        Breast Cancer Chemotherapy Varies Widely: Study Raises Questions About Early Treatment Choices
        Forbes
        13 August 2014
        373 Citations
        Citation Type

        Citation Type

        Trastuzumab for HER2-Positive Breast Cancer: A Major Step Forward
        From tumor size and HER2 status to systems oncology for very early breast cancer treatment
        • 67
        Cytokeratin profiles of male breast cancers
        • 33
        • PDF
        The art of prescribing trastuzumab for HER2-positive breast cancer
        • 1
        Cancers du sein : évolution des grands concepts thérapeutiques
        • 5
        HER2 status in breast cancer--an example of pharmacogenetic testing.
        • 25
        HER2 status in breast cancer–an example of pharmacogenetic testing
        Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
        • 284
        • PDF
        Retraction Note to: SOX2 oncogenes amplified and operate to activate AKT signalling in gastric cancer and predict immunotherapy responsiveness
        • PDF
        Triple negative invasive lobular carcinoma of the breast presents as small bowel obstruction

        References

        SHOWING 1-6 OF 6 REFERENCES
        Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
        • 4,487
        • PDF
        Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
        • 1,324
        • PDF
        Untangling the ErbB signalling network
        • 5,941
        • PDF
        Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
        • 4,905
        • PDF
        Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
        • 10,825
        • PDF
        Molecular portraits of human breast tumours
        • 13,022
        • PDF